PMID: 69782Jul 23, 1977Paper

Antibody-drug synergism: An assessment of specific passive immunotherapy in bronchial carcinoma

Lancet
C E Newman, C H Ford

Abstract

Patients with bronchial carcinoma who had had radical resection of the primary tumour were treated with a combination of drugs and tumour-specific immunoglobulin (antibody-drug synergism, A.D.S.). The antisera were raised in goats by immunisation with tumour cells from patients, and given to those patients after absorption to remove antibody against normal human tissues. 32 patients received A.D.S. treatment and 37 patients received chemotherapy only. Although the differences are not statistically significant there have been 22 recurrences including 15 deaths in the chemotherapy group and 8 recurrences including 6 deaths in the A.D.S group. There was only one clinically significant reaction to heterologous immunoglobulin.

Citations

Jan 1, 1983·Pharmacology & Therapeutics·D C Edwards
Feb 1, 1979·British Journal of Obstetrics and Gynaecology·C N Hudson
Jan 1, 1982·Immunological Reviews·R A De WegerW Den Otter
May 15, 1986·International Journal of Cancer. Journal International Du Cancer·E HurwitzJ Haimovich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Bronchogenic

Bronchogenic Carcinoma is a malignant lung cancer arising in the epithelium of the bronchus or bronchiole. Discover the latest research on Bronchogenic Carcinoma here.

Related Papers

Bulletin of the Pan American Health Organization
E C Norrby
Cancer Chemotherapy and Pharmacology
H F Dullens, R A De Weger
© 2021 Meta ULC. All rights reserved